A-share solid-state battery concept stocks hit bottom and rebounded. Jiangte Motor hit the daily limit in the afternoon, Liyuanheng rose more than 10%, and Jiaocheng Ultrasonics, Huitian New Materials, Tianqi Lithium, and Shanshan Holdings were among

Brazilian Finance Minister Haddad: We should see food deflation in the coming months.

Stock News: 1. Yum China (09987.HK): Net profit in the first half of the year was US$507 million, a year-on-year increase of 1.6%. 2. Yue Yuen Group (00551.HK): Profit attributable to shareholders in the first half of the year was US$171 million, a year-on-year decrease of 7.2%. 3. Tingyi Holdings (00322.HK): Profit attributable to shareholders in the first half of the year was RMB 2.271 billion, a year-on-year increase of 20.5%. 4. YTO Express (06123.HK): Net loss in the first half of the year is expected to increase to approximately HK$56 million to HK$65 million. 5. Highland Holdings (01676.HK) plans to acquire 100% equity in Able Talent Asia Limited for RMB 20 million. 6. Greenland Hong Kong (00337.HK): Contract sales in the first seven months were approximately RMB 3.472 billion, a year-on-year decrease of 28.31%. 7. Vietnam Manufacturing Processing and Export (00422.HK): Profit attributable to shareholders was US$42,500 in the first half of the year, turning a profit year-on-year. 8. Future Land Development (01030.HK): Contract sales for the first seven months totaled approximately RMB 11.99 billion, a year-on-year decrease of 55.66%. 9. Lepu Bio-B (02157.HK): Its independently developed TF ADC drug MRG004A was designated a breakthrough therapy. 10. Pou Sheng International (03813.HK): Net operating income for the first seven months totaled RMB 10.3135 billion, a year-on-year decrease of 8.3%. 11. Hopson Development Holdings (00754.HK): Contract sales for the first seven months totaled approximately RMB 9.047 billion, a year-on-year decrease of 12.49%. 12. Sany International (00631.HK): Net profit for the first half of the year is expected to be approximately 1.234 billion to 1.332 billion yuan, a year-on-year increase of 25%-35%. 13. Fosun Pharma (02196.HK): The innovative small molecule drug XH-S004 has secured overseas rights for licensing, with a potential total value of US$645 million. 14. Hengrui Medicine (01276.HK): Trastuzumab Injection and Adebelimumab Injection have been included in the public list of proposed breakthrough therapy products.